Dr. Barrientos on the Impact of Combinations in CLL

Video

In Partnership With:

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia (CLL).

Combinations offer the opportunity to treat certain patients who would not be optimally treated with the currently available regimens, says Barrientos. This is particularly true for patients older than 65, as they traditionally do not do well with a chemotherapy regimen like fludarabine, cyclophosphamide, and rituximab (Rituxan). Barrientos says that even patients in their 80s can undergo combination therapy.

Combination studies like TAP CLARITY, which evaluated ibrutinib (Imbruvia) plus venetoclax (Venclexta) in patients with relapsed/refractory CLL, have shown that combinations elicit deep responses with no increase in toxicity. Based on studies like these, Barrientos says that there is a possibility of a future with chemotherapy-free regimens for patients with CLL. This will provide the opportunity for patients to achieve deeper responses so that they do not need to be on a drug indefinitely, she adds.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute